The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | EMPOWER-Lung 3: 5-year results of cemiplimab & chemotherapy in NSCLC
Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, discusses 5-year results from Phase III EMPOWER-Lung 3 (NCT03409614) of cemiplimab plus chemotherapy versus chemotherapy in untreated advanced non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 alterations. The combination demonstrated sustained improvements in overall and progression-free survival, response rates, and duration of response across histologies and PD-L1 subgroups. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So EMPOWER-Lung 3Part 2 is a randomized double-blind placebo-controlled phase 3 study where patients with non-small cell lung cancer without actionable genomic mutations regardless of PD-L1 expression level or histology were randomized to receive cemiplimab or placebo plus four cycles of chemotherapy. And we are presenting, we presented in WCLC, five-year outcomes of the data, and we had really good results related to the overall survival...
So EMPOWER-Lung 3Part 2 is a randomized double-blind placebo-controlled phase 3 study where patients with non-small cell lung cancer without actionable genomic mutations regardless of PD-L1 expression level or histology were randomized to receive cemiplimab or placebo plus four cycles of chemotherapy. And we are presenting, we presented in WCLC, five-year outcomes of the data, and we had really good results related to the overall survival. So 21.1% of patients achieved overall survival with the patients who have been treated with cemiplimab plus chemotherapy versus 12.9 months. and it’s an overall survival and the hazard ratio was 0.662 and also we have very favorable objective response rate cemiplimab plus chemotherapy favored like 44% objective response versus 22% for the chemotherapy and the PFS is also 8.1 months versus 5.5 months. So in overall, just in all aspects, cemiplimab favored, cemiplimab plus chemotherapy favored chemotherapy alone.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
